March 2025 • PharmaTimes Magazine • 36-37
// YOUR MOVES //
Your Moves
Movers of the Month
Glox Therapeutics has announced the appointment of Dr Michael Murray as Chair of the Board. He will work with the team to accelerate growth and help guide the commercialisation of its technology.
The company has also expanded its scientific advisory board, adding Dr Nel Moore. She will support the development of novel engineered protein bacteriocins to target drug-resistant pathogenic bacteria and help overcome antimicrobial resistance.
Michael is the Principal at Murray International Partners. He has led multiple high-value international deals in the life sciences sector using his expertise in intellectual property management, market assessment and deal-making to support various organisations.
He has nearly 30 years’ experience in senior and interim management roles at several biotech and pharma companies. These include Metallobio, Porton Biopharma, EnteroBiotix, Sosei Heptares and Amura Therapeutics.
Michael teaches commercial IP strategy on the Novo Nordisk Fellowship MBA in BioMedical Design programme. He has delivered training to over 1,200 individuals in the commercialisation of technical innovations since 2015.
He is also a Member of The Royal Society Industry College, an Entrepreneur in Residence at the University of Sheffield and a Mentor at Cambridge Enterprise. Michael holds a PhD in Molecular Cell Biology from the University of Leicester.
Nel has vast expertise in global drug discovery, development and commercialisation in immunology, oncology and anti-infectives.
Formerly, Vice President of Antibiotics Development at AstraZeneca, she led the late-stage development, global regulatory submission and approval of Zavicefta/Avycaz for multidrug-resistant bacterial infections. She later built and led AstraZeneca’s antibiotics development organisation before its divestment to Pfizer.
Aspire Pharma has announced the appointment of Katy Carroll as Country Director of APIE Ltd. She will be based in Dublin, Ireland.
Katy has joined Aspire during a period of significant growth for the company. With the recent set-up of this new country office, she will add to the focused strategy of its international expansion.
As a senior pharmaceutical growth leader, Katy brings over 35 years’ experience in the pharmaceutical sector. Her last role was as a Business Unit Manager, Specialty Medicine, for Bayer Healthcare in Ireland.
Doceree has announced the appointment of Ritesh Patel as Chief Growth Officer. He will expand Doceree’s presence in the US and key global markets.
In his new role, Ritesh will lead growth initiatives, expand strategic partnerships and accelerate global adoption of Doceree’s innovative solutions. These solutions are especially aimed at enriching HCP-patient conversations in the point-of-care space.
A leader with over two decades of experience, Ritesh brings expertise in digital transformation and emerging technologies to Doceree. He has received multiple accolades, including the UN Leadership Council Award, PharmaVoice 100 Inspiring Leader and a Clio Award.
Previously, as the Managing Partner, Global Digital Health at Finn Partners, Ritesh played a pivotal role in driving digital transformation and strategic innovation. He has been at the forefront of shaping and driving conversations around point-of-care (POC) marketing in healthcare.
Ritesh advocated for POC's critical role in delivering relevant, data-driven messaging to healthcare professionals at the moment of care. As he joins Doceree, he will continue to drive initiatives in this space.
4basebio has announced the appointment of Gabe Longoria as Chief Commercial Officer.
Gabe's expertise in scaling commercial operations will play a crucial role in ensuring the company's synthetic DNA products reach their full market potential. The company is well-positioned to deliver on its growth and commercialisation goals in 2025 and beyond.
Gabe joins 4basebio following a successful tenure as Chief Commercial Officer at Astrea Bioseparations. During his leadership, Gabe supported the company in achieving exceptional financial growth. He doubled revenues over a three-year period and expanded its market share globally.
His strategic approach to scaling operations and fostering key partnerships solidified Astrea’s position as a leader in biopharmaceutical manufacturing solutions.
Gabe has over two decades of commercial leadership in the life sciences sector. He has expertise in driving revenue growth, market expansion and strategic partnerships for companies.
Commenting on his new role, Gabe said: "I am incredibly excited to join 4basebio at such a transformative stage in its journey. The company’s groundbreaking synthetic DNA technology has the potential to revolutionise the gene therapy and vaccine industries. I am eager to help bring these innovative products to a global audience."
Grünenthal has announced that Professor Dr Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board.
Uli has more than 15 years of industry experience. He joins Grünenthal from Boehringer Ingelheim, where he served as Corporate Senior Vice President, Head of Global Clinical Development & Operations, and member of Boehringer Ingelheim's Venture Fund Investment Committee.
In his most recent role, he oversaw end-to-end clinical development and operations activities across therapeutic areas. He worked at the interface of R&D, Commercial and Market Access functions. He has a proven track record of bringing innovative medicines to patients, including Empagliflozin, an oral anti-diabetic medicine.
Earlier in his career, Uli led Boehringer Ingelheim's Canadian medical organisation and gained extensive market experience. In parallel, he founded and co-chaired the BI Canada Incubator, an innovation lab to develop innovative healthcare solutions.
Uli graduated as a Medical Doctor from Ludwig-Maximilians University Munich. He is a board-certified internist and endocrinologist and an Adjunct Professor of Internal Medicine at the Ludwig Maximilan University of Munich.
"The unique focus on improving the quality of life of underserved patients suffering from pain attracted me to Grünenthal,” says Uli. "I look forward to joining the team and further driving Grünenthal’s innovation pipeline."
"With Uli, we have been able to attract an excellent leader," says Gabriel Baertschi, CEO of Grünenthal. "His extensive experience in R&D and commercial functions combined with Uli's drive to bring innovative medicines to patients will help us propel our vision of a world free of pain."
Kenvue has appointed Bas Vorsteveld as Area Managing Director for Northern Europe. He will oversee Kenvue’s business in the UK, Ireland, Norway, Sweden, Denmark and Finland.
Bas will manage a portfolio of iconic brands including Nicorette, Aveeno, Johnson’s Baby, Listerine, Neutrogena, Calpol, OGX and Imodium.
Carlton Lawson, Group President for Europe, Middle East, Africa and Latin America at Kenvue, said: “We are excited to welcome Bas as Area Managing Director for Kenvue in Northern Europe. With almost three decades of experience in consumer goods and healthcare, Bas brings a proven track record of delivering industry leading growth."
Bas said: “Kenvue’s iconic brands speak for themselves. I am excited by the truly holistic approach to self-care we can offer through the entire range of different categories we thrive in.”
Prior to joining Kenvue, Bas held the position of Vice President & General Manager for Great Britain and Ireland at Haleon. He played a critical role in driving the GBI business, separating it from GSK while delivering industry-leading growth.
Bas was until recently President of the Board of the PAGB. He launched the organisation’s five-year strategy focusing on how the industry can support the government in alleviating healthcare pressures through promoting self-care.
Previously, Bas held several roles across Europe with GSK Consumer Healthcare, including VP & Head of Commercial Excellence EMEA, VP & General Manager France and French-speaking Africa & Maghreb, and GM Benelux. Prior to that, he held GM roles at Novartis. Bas started his career at Campina.
OPEN Health has announced the appointment of David Sakadelis as Chief Technology Officer.
In this role, David will be responsible for enhancing its services through technology-enabled solutions for biopharma partners, focusing on solving challenges and driving innovation in its Solution Innovation Center.
OPEN Health’s Solution Innovation Centre (SIC) consists of a cross-functional team. It leverages technology partnerships to combine scientific expertise and proprietary product development.
The goal is to advance biopharmaceutical innovation in Medical Affairs and market access. An experienced executive with over 25 years of expertise, David has led a wide range of projects.
This includes 13 years in biopharma with Publicis Health and Klick Health. Notably, he spearheaded the development of connected patient services using innovative tools.
These tools address patient adherence and enhance patient-doctor communication. This suite of services has been recognised as a significant advancement for biopharma in patient engagement.
It stands as a testament to David’s ability to effectively apply technology to addressing healthcare needs. In addition to his work on connected patient services, David has led the strategy and technical implementation for transformative content production.
“David’s strategic vision, technical acumen and passion for leveraging technology to solve complex business challenges make him an ideal fit for OPEN Health,” said Steve Duryee, Chief Operating and Transformation Officer of OPEN Health.
PharmaTimes
PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.